In an era when antibiotic-free farming is no longer a niche aspiration but a regulatory and commercial reality, scientists are turning their attention to the trillions of microbes that inhabit the guts of food-producing animals. A new field study published in Applied Microbiology and Biotechnology offers a rare, real-world glimpse into how the intestinal microbiota of free-range laying hens responds when disease strikes a commercial flock—and what happens when those birds are fed a so-called precision biotic designed to steer their microbial communities in a healthier direction.
The research, led by Friedrich Petranyi and Yadav S. Bajagai of the Institute for Future Farming Systems at Central Queensland University in Australia, together with colleagues including Dragana Stanley and veterinary researcher Ivan Milošević of the University of Belgrade, documents a commercial layer operation that endured not one but three separate disease outbreaks over the course of the observation period. Two distinct pathogens were involved: one causing spotty liver disease, a bacterial condition associated with the organism Campylobacter hepaticus that produces characteristic lesions on the liver and can sharply reduce egg production and increase mortality, and another causing fowl cholera, an acute and often devastating infection driven by Pasteurella multocida. Encountering both diseases concurrently or in sequence within the same flock is an uncommon and scientifically valuable event, precisely because laboratory experiments almost never manage to reproduce such layered, messy, real-world conditions.
That gap between the laboratory and the farm is central to the motivation behind the study. As the authors explain, experiments conducted in high-biosecurity animal houses approved under strict ethical standards cannot ethically or practically induce lethal outbreaks, and even when pathogens are introduced deliberately, the environmental complexity of a commercial free-range operation—variable weather, soil exposure, wild bird and rodent contact, stocking density fluctuations, and the accumulated management history of a real farm—is impossible to replicate. Field observations during naturally occurring outbreaks therefore provide a kind of data that controlled experiments simply cannot generate, even though such observations come with important caveats. The research team was careful to note that because this was an unreplicated field study involving a single flock, the differences they observed between supplemented and control birds should be interpreted as descriptive associations rather than proof of cause and effect.
The intervention at the heart of the study was a precision biotic, described by the researchers as a synthetic glycan product. Precision biotics belong to a class of feed additives engineered to selectively nourish beneficial members of the gut microbiota rather than broadly supplementing the diet. Unlike antibiotics, which kill or suppress bacteria indiscriminately, glycans act as targeted substrates: they are designed to be fermented by specific desirable microbes in the distal gut, encouraging those organisms to flourish and, in theory, to crowd out or outcompete pathogens while producing beneficial metabolites such as short-chain fatty acids. The concept reflects a broader shift in livestock science away from blunt antimicrobial tools and toward ecological management of the intestinal ecosystem—a shift driven largely by mounting global concern over antimicrobial resistance.
Over the course of the trial, the researchers tracked two broad categories of outcomes. The first was performance: birds receiving the precision biotic were compared with unsupplemented control birds on weekly measures, including egg output and cumulative mortality. The second was microbial: the team profiled the gut microbiota across the major anatomical sections of the intestinal tract, from the proximal regions through to the ceca, which harbor the densest and most metabolically active microbial populations in poultry. By sampling repeatedly during and between the three outbreaks, the investigators were able to observe how the microbial communities shifted not only in response to the supplement but also in response to the wave of pathogen pressure sweeping through the flock.
The headline findings were, in the authors’ own framing, a study in trade-offs. Birds that received the precision biotic showed higher cumulative mortality than the control group—a result that might, at first glance, appear to condemn the intervention. Yet the same supplemented group also achieved higher cumulative egg output, meaning that despite losing more birds, the supplemented flock produced more eggs overall. The researchers are explicit that this counterintuitive pairing cannot be causally interpreted given the unreplicated design. It is possible, for instance, that the supplemented group happened to face a heavier pathogen challenge in their section of the farm, or that subtle management differences influenced outcomes; equally, the higher mortality may reflect a genuine biological trade-off in which a more productive microbiota-supported metabolism also carried costs during severe disease pressure. What the study demonstrates most clearly is that under real-world outbreak conditions, single-metric evaluations of feed additives can be misleading, and that both survival and productivity must be considered together.
Alongside the performance data, the microbial analysis revealed that the composition of the intestinal microbiota responded differently to supplementation depending on where along the gut the samples were taken and what disease pressures were operating at the time. The researchers also observed differences in liver congestion between the supplemented and control groups at post-mortem examination. Liver pathology is a particularly relevant endpoint in this context, because spotty liver disease manifests as congestion and necrotic spotting of the liver, and the gut–liver axis—the bidirectional relationship between intestinal microbes, their metabolites, and hepatic health—is increasingly recognized as a critical determinant of disease outcomes in poultry. Microbial products absorbed from the intestine reach the liver via the portal circulation, and shifts in the gut community can therefore translate directly into changes in hepatic inflammation and pathology.
The broader backdrop to this work is the intensifying pressure on the poultry industry to reduce its reliance on antibiotics. Historically, intensive poultry production was built in part on the routine use of subtherapeutic antibiotics, which promoted growth and controlled disease. Growing evidence of antimicrobial resistance—the transfer of resistance genes from livestock-associated bacteria to human pathogens—has prompted bans and voluntary phase-outs in many countries. Free-range systems face an especially acute dilemma: consumers perceive them as more welfare-friendly, and regulations often restrict antimicrobial interventions, yet the very freedom that defines these systems exposes birds to soil-borne pathogens, wild fauna, and environmental stressors that raise disease risk. Spotty liver disease, in particular, is strongly associated with free-range and floor-raised flocks, and its incidence has grown in parallel with the expansion of free-range egg production. The result is a system in which disease pressure is rising just as the tools for controlling it are being withdrawn.
This is where the microbiota-focused approach gains its appeal. The gut microbiota of laying hens performs a suite of functions that influence both health and productivity: it aids in the digestion of complex plant fibers in the diet, synthesizes vitamins, trains the immune system, and forms a competitive barrier against pathogens such as Salmonella, Campylobacter, and Pasteurella. Precision glycans exploit this biology by acting as selective fertilizers for the microbial taxa that perform these beneficial functions. The Australian study adds to a growing body of evidence that such additives can meaningfully reshape the gut ecosystem in production animals, while simultaneously serving as a cautionary reminder that the consequences of reshaping it during active disease outbreaks are far from predictable.
The authors emphasize that the value of their work lies not in any single result but in the scale and realism of the observation. Field studies of this kind—tracking performance measures weekly, profiling gut microbiota across multiple intestinal segments, and doing so across three naturally occurring outbreaks—are rare in the published literature, both because access to commercial farms is difficult and because documenting an outbreak as it unfolds requires the good fortune of having sampling infrastructure already in place. The data set therefore constitutes a reference point for the microbial signatures associated with concurrent spotty liver disease and fowl cholera in a free-range flock, something that future controlled studies can use to generate and test specific hypotheses about which microbial taxa protect against, or exacerbate, these diseases.
The study also carries practical implications for how the industry evaluates feed additives. If a precision biotic can increase egg output while apparently increasing mortality under severe disease pressure, then farm-level decision-making about supplements must weigh production gains against health risks, and trials designed to test such products should ideally include replication, blinding, and long enough observation windows to capture outbreak conditions. The researchers suggest that their observations may inform future controlled studies of disease dynamics and performance management, effectively positioning the field data as a hypothesis-generating foundation rather than a definitive verdict on precision biotics.
Funding for the work came in part from DSM-Firmenich, a major animal nutrition and ingredients company, through a PhD scholarship program; several of the authors are employed by or hold scholarships connected to the company, a conflict of interest that the authors disclose transparently in the paper. The study was approved by the Central Queensland University Animal Ethics Committee. The research team notes that no artificial intelligence tools were used to generate content or analyze the results, and that the entire study was produced by the research team itself.
As antimicrobial resistance continues to constrain the toolkit available to animal agriculture, studies like this one highlight both the promise and the difficulty of managing animal health from the inside out. The microbial ecosystem in a hen’s gut is a moving target, shaped by diet, genetics, environment, and disease—and no single additive can guarantee protection when pathogens are circulating on a real farm. What the Australian team has delivered is something arguably more useful than a clean laboratory result: an honest, detailed record of what actually happens when a commercial free-range flock fights two serious bacterial diseases while half its members eat a diet designed to feed their beneficial microbes. It is precisely this kind of unvarnished, on-farm evidence that will be needed if the poultry industry is to navigate its post-antibiotic future successfully, and if scientists are to design the next generation of controlled experiments with their feet planted firmly in the realities of commercial production.
Subject of Research: Gut microbiota dynamics in free-range layer hens during field outbreaks of spotty liver disease and fowl cholera, and the effects of a synthetic glycan precision biotic on hen performance and mortality.
Subject of Research: Biology
Article Title: Gut microbiota dynamics in free-range layer hens during outbreaks of spotty liver disease and fowl cholera—a field study
Article References: Petranyi, F., Whitton, M. M., Lobo, E., Yu, S. J., Milošević, I., Stanley, D., & Bajagai, Y. S. (2026). Gut microbiota dynamics in free-range layer hens during outbreaks of spotty liver disease and fowl cholera—a field study. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-13965-0
Image Credits: AI Generated
DOI: 10.1007/s00253-026-13965-0
Keywords: Gut microbiota, Free-range layer hens, Spotty liver disease, Fowl cholera, Precision biotic, Synthetic glycan, Antimicrobial resistance, Poultry health, Egg production, Gut-liver axis, Microbiome dynamics, Field study
Cite Scienmag News
APA MLA Chicago
Morgan Morrow. (September 7, 2026). Gut bacteria shifts in free-range hens during disease outbreaks. Scienmag. https://scienmag.com/gut-bacteria-shifts-in-free-range-hens-during-disease-outbreaks/
Morgan Morrow. “Gut bacteria shifts in free-range hens during disease outbreaks.” Scienmag, 7 September 2026, https://scienmag.com/gut-bacteria-shifts-in-free-range-hens-during-disease-outbreaks/. Accessed 7 September 2026.
Morgan Morrow. “Gut bacteria shifts in free-range hens during disease outbreaks.” Scienmag. September 7, 2026. https://scienmag.com/gut-bacteria-shifts-in-free-range-hens-during-disease-outbreaks/
Copy citation Download RIS
Tags: antibiotic-free farming and gut microbiome managementantibiotic-free poultry farming and gut health managementeffects of bacterial pathogens like Campylobacter hepaticus and Pasteurella multocida on laying henseffects of precision biotics on poultry gut healthgut microbiome response to fowl cholera outbreaksGut microbiota changes in free-range hens during disease outbreaksimpact of bacterial pathogens on laying hensimpact of precision biotics on poultry gut healthinterventions to steer poultry gut microbiota toward healthmicrobial community dynamics in free-range egg productionmicrobial community steering in free-range hensmicrobial shifts during spotty liver disease in chickensmicrobiome shifts in commercial poultry during infectionmicrobiome-basedpathogen influence on intestinal microbiota in poultryreal-world studies of poultry gut microbiota during disease outbreaksreal-world study of poultry microbiota during disease eventsrole of gut microbes in poultry disease resistancerole of intestinal microbes in poultry disease resistance
